IMMUNOPRECISE ANTIBODIES LTD. (NASDAQ: HYFT)

IMMUNOPRECISE ANTIBODIES LTD.

NASDAQ: HYFT (MindWalk Holdings Corp.)

Last update: 15 hours ago

1.76

-0.45 (-20.36%)

Add to watchlist

Previous Close	2.21
Open	2.26
Volume	11,253,259
Avg. Volume (3M)	1,906,779
Market Cap	81,231,216

Price / Sales	3.56
Price / Book	5.11

52 Weeks Range	0.270 (-84%) — 3.25 (84%)
Earnings Date	15 Sep 2025

AIStockmoo Score

-0.6

Analyst Consensus	0.0
Insider Activity	NA
Price Volatility	-4.5
Technical Moving Averages	2.5
Technical Oscillators	-0.5
Average	-0.63

Ownership

Name	Date	Shares Held
Gradient Capital Advisors, Llc	30 Jun 2025	26,808
Tradition Wealth Management, Llc	30 Jun 2025	13,177

No data within this time range.

Date	Type	Details
15 Sep 2025	Announcement	MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet
10 Sep 2025	Announcement	MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
03 Sep 2025	Announcement	ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”
02 Sep 2025	Announcement	ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
27 Aug 2025	Announcement	ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation
06 Aug 2025	Announcement	ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation
29 Jul 2025	Announcement	ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA
24 Jul 2025	Announcement	ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic
21 Jul 2025	Announcement	ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board
16 Jul 2025	Announcement	IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025
14 Jul 2025	Announcement	ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
07 Jul 2025	Announcement	ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors
03 Jul 2025	Announcement	ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data
24 Jun 2025	Announcement	ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)